Role of plasma insulin concentration in regulating glucose and lipid metabolism in lean and obese Zucker rats

International Journal of Obesity

Volumn 21, Issue 2, 1997, Pages 115-121

  Noshiro, O ^a   Hirayama, R ^a   Shimaya, A ^a   Yoneta, T ^a   Niigata, K ^a   Shikama, H ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Insulin sensitizer thiazolidinedione; Lipid metabolism; Obese Zucker rat; Plasma insulin concentration; YM268

Indexed keywords

CHOLESTEROL; FATTY ACID; GLUCOSE; INSULIN; LIPID; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031018421     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0800375     Document Type: Article

References (28)

1. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Rosner B, Monson RR, Speizer FE, Hennekens CH. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322: 882-889.
2. Faber OK, Christensen K, Kehlt H, Madsbad S, Binder C. Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab 1981; 53: 618-621.
3. Olefsky JM, Nolan JJ. Insulin resistance and non-insulin-dependent diabetes mellitus: cellular and molecular mechanisms. Am J Clin Nutr 1995; 61 (suppl): 980S-986S.
4. Stout RW. Insulin and athroma: 20-yr perspective. Diabetes Care 1990; 13: 631-654.
5. Karhapaa P, Malkki M, Laakso M. Isolated low HDL cholesterol: an insulin-resistant state. Diabetes 1994; 43: 411-417.
6. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
7. Ikeda H, Shino A, Matsuo T, Iwatsuka H, Suzuoki Z. A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes 1981; 30: 1045-1050.
8. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978; 14: 141-148.
9. Kodama H, Fujita M, Yamaguchi I. Development of hyperglyceamia and insulin resistance in conscious genetically diabetic (C57BL/KsJ-db/db) mice. Diabetologia 1994; 37: 739-744.
10. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H. Characterization of new oral antidiabetic agent CS-045; Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 1988; 37: 1549-1558.
11. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arznein-Forch/Drug Res 1990; 40: 156-162.
12. Stevenson RW, Hutson NJ, Krupp MN, Volkmann RA, Holland GF, Eggler JF, Clark DA, McPherson RK, Hall KL, Danbury BH, Gibbs EM, Kreutter DK. Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes 1990; 39: 1218-1227.
13. y mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol. Am J Physiol 1994; 267: E95-E101.
14. Sugiyama Y, Shimura Y, Ikeda H. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty acids. Arzneim-Forch/Drug Res 1990; 40: 436-440.
15. Kobayashi M, Iwanishi M, Egawa K, Shigeta Y. Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 1992; 41: 476-483.
16. Burstein M, Scholnick H, Morfin R. Rapid method for isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res 1970; 11: 583-595.
17. Lillioja S, Mott DM, Howard BV, Bennet PH, Yki Jarvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima indians. N Engl J Med 1988; 318: 1217-1225.
18. Islam AHMW, Yamashita S, Kotani K, Nakamura T, Tokunaga K, Arai T, Nishida M, Kameda-Takamura K, Matsuzawa Y. Fasting plasma insulin level is an important risk factor for the development of complications in Japanese obese children-Results from a cross-sectional and a longitudinal study. Metabolism 1995; 44: 478-485.
19. Bowen L, Stein PP, Stevenson R, Shulman GI. The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism 1991; 40: 1025-1030.
20. Gylling H, Miettnen TA. Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholestelaemic NIDDM patients before and during sitostanol ester-margarine treatment. Diabetologia 1994; 37: 773-780.
21. Yamada N, Yoshinaga H, Sakurai N, Shimano H, Gotoda T, Ohashi Y, Yazaki Y, Kosaka K. Increased risk factors for coronary artery disease in Japanese subjects with hyperinsulinemia or glucose intolerance. Diabetes Care 1994; 17: 107-114.
22. Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, Kirkham DM, Lister CA, Smith SA. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Diabetes 1995; 44: 1087-1092.
23. de Souza CJ, Yu JH, Robinson DD, Ulrich RG, Meglasson MD. Insulin secretory defect in Zucker fa/fa rats is improved by ameriolating insulin resistance. Diabetes 1995; 44: 984-991.
24. Masuda K, Okamoto Y, Tsuura Y, Kato S, Miura T, Tsuda K, Horikoshi H, Ishida H, Seino Y. Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 1995; 38: 24-30.
25. Felber J-P, Ferrannini E, Golay A, Meyer HU, Trebraund D, Chrchod B, Meader E, Jequier E, DeFronzo RA. Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes 1987; 36: 1341-1350.
26. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; 1: 785-789.
27. Kobayashi M, Shigeta Y, Hirata Y, Omori Y, Sakamoto N, Nanbu S, Baba S. Improvement of glucose tolerance in NIDDM by clofibrate: randomized double blind study. Diabetes Care 1988; 11: 495-499.
28. Fulcher GR, Walker M, Catalano C, Agius L, Alberti KGMM. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes 1992; 41: 1400-1408.